Leading Tac

Based in Shanghai, China and founded in 2019, Shanghai Leadingtac Pharmaceutical Co. , Ltd. , trading as Leading Tac, operates as a biopharmaceutical company that focuses on the development of an innovative small molecule drug. In 2023, the company acquired approval from China's NMPA.

In December 2025, Leading Tac raised over CNY 200 million in series B funding led by new investor Hankang Capital, with participation from new investors CDH Investments, Shanghai Kangcheng Investment Management, New Day Fund and returning investor Lapam Capital. The company's main business is the research and development of innovative small molecule drugs. It established two biopharmaceutical platforms, which are Nano-SPUD and Lyso-SPUD. Nano-SPUD is a targeted protein ubiquitination and degradation platform for the screening and development of intracellular proteins and E3 ligases.

Its IRAK4 degrader can be used to treat atopic dermatitis, rare autoimmune diseases, AML, MDS and other blood tumor diseases. The company generates revenue by providing innovative small molecule drugs. The company will use the latest funding to accelerate clinical development of its core pipeline and upgrade its R&D platform, including advancing IRAK4 degrader LT-002 through Phase Ic and II trials, initiating Phase I trials for KRAS G12D degrader, expediting preclinical work on autoimmune and oncology programs, and supporting full operations of the Shaoxing R&D center with team expansion.